NCT05729074 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

February 25, 2023

Study Completion Date

January 31, 2024

Conditions

Mild to Moderate Atopic Dermatitis

Interventions

DRUG

IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment

Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

DRUG

IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment

Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day

DRUG

IN-A002 Ointment 1% or IN-A002 Placebo Ointment

Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

DRUG

IN-A002 Ointment 3% or IN-A002 Placebo Ointment

Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

DRUG

IN-A002 Ointment 5% or IN-A002 Placebo Ointment

Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

DRUG

IN-A002 Ointment 1%

Drug: IN-A002 Ointment 1%, 3 g/1000 cm2

DRUG

IN-A002 Ointment 3%

Drug: IN-A002 Ointment 3%, 3 g/1000 cm2

DRUG

Elidel Cream 1% (pimecrolimus)

Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2